Blog

TORONTO, ONTARIO / ACCESS Newswire / May 27, 2025 / Electrovaya Inc. (Nasdaq:ELVA)(TSX:ELVA), a leading lithium-ion battery technology and manufacturing company, today announced that it will host an investor webcast presentation on June 3, 2025 at 2:00 PM EDT.

During the webcast, Dr. Raj DasGupta., CEO and John Gibson, CFO, will conduct an introductory presentation that will cover key aspects of Electrovaya’s business including corporate strategy, business model, and industry-leading technology. After the formal presentation, investors will have an opportunity to ask relevant questions through an interactive Q&A portal.

https://us02web.zoom.us/webinar/register/WN_QU4ncWdfRaWS5hVR_-ptkg

Investor and Media Contact:

Jason Roy
VP, Corporate Development and Investor Relations
Electrovaya Inc.
jroy@electrovaya.com / 905-855-4618

About Electrovaya Inc.

Electrovaya Inc. (NASDAQ:ELVA) (TSX:ELVA) is a pioneering leader in the global energy transformation, focused on contributing to the prevention of climate change by supplying safe and long-lasting lithium-ion batteries. The Company has extensive IP and designs, develops and manufactures proprietary lithium-ion batteries and battery systems for energy storage and heavy duty electric vehicles based on its Infinity Battery Technology Platform. This technology offers enhanced safety and industry leading battery longevity. The Company is also developing next generation solid state battery technology at its Labs division. Headquartered in Ontario, Canada, Electrovaya has two operating sites in Canada and has acquired a 52-acre site with a 135,000 square foot manufacturing facility in New York state for its planned gigafactory. To learn more about Electrovaya, please explore www.electrovaya.com.

SOURCE: Electrovaya, Inc.

View the original press release on ACCESS Newswire

Ambience’s latest AI model reduces coding errors and targets $266 billion in annual administrative waste

SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2025 / Ambience Healthcare today announced a major advancement in ambient AI, unveiling the first AI model that outperforms board-certified physicians in ICD-10 coding accuracy.

Trained using OpenAI’s Reinforcement Fine-Tuning (RFT) technology, Ambience’s AI platform achieved a 27% relative improvement over physician benchmarks-reducing coding errors by approximately one-quarter and offering a powerful tool to tackle the $266 billion in annual administrative waste, including $19 billion in diagnosis coding & documentation substantiation errors.

This new model identifies precise ICD-10 codes based on patient encounters, which feed into Ambience’s ‘coding-aware’ scribe. By leveraging these codes first, the scribe generates a fully informed note-allowing clinicians to review and confirm accurate documentation and coding in real time.

“Think of this technology as a scribe that fluently speaks both clinical language and the intricate healthcare billing rulebook from day one,” said William H. Morris, MD, MBA, Chief Medical Officer of Ambience Healthcare. “Our platform helps clinicians finish their notes faster and ensures that revenue cycle teams receive cleaner, more accurate, and audit-ready charts.”

Ambience is live across inpatient, outpatient, and emergency settings at health systems throughout the United States, supporting over 100 medical specialties with real-time, compliant documentation. Clinicians at more than 40 organizations including UCSF Health, St. Luke’s Health System, Houston Methodist, John Muir Health, and Memorial Hermann Health System leverage Ambience before, during, and after patient encounters to generate compliant documentation, alleviate burnout, and enhance care quality.

How Ambience’s “Coding-Aware” AI Scribe Works
Ambience Healthcare’s platform streamlines the clinical documentation and coding process:

• Clinicians simply tap ‘Record’ on their device, conduct patient visits as usual, and then review a draft note, complete with suggested ICD-10 and CPT codes;

• Ambience integrates natively with major EHRs-including Epic, Oracle Cerner, and athenahealth-ensuring that after clinicians review and sign off, the complete and coded documentation is automatically filed back into the patient’s record;

• By addressing coding at the point of care, Ambience eliminates downstream compliance issues and the time-consuming back-and-forth queries between clinicians and coding/billing departments.

“We built for compliance at the core of our platform because health systems need assurance that AI technology in the workflow can stand up to audits, protect reimbursement, and support clinical documentation integrity,” said Michael Ng, CEO and Co-Founder of Ambience Healthcare. “The stakes of getting this wrong are too high for compliance to be an afterthought.”

Validated Results with RFT Technology
To validate its AI’s mastery of the “coding rulebook,” Ambience assembled a “gold-panel” test dataset of complex clinical cases spanning multiple medical specialties. Each encounter was meticulously labeled by a consensus of four or more expert clinicians to establish a high-quality ground truth.

“Reinforcement Fine-Tuning lets developers align powerful AI models with the precision and robustness that high-stakes domains like healthcare demand,” said Shyamal Anadkat, Head of Startup Solutions at OpenAI. “Ambience’s results show how RFT can lift the performance of AI systems in safety-critical environments”.

The Ambience model was benchmarked against 18 experienced, board-certified physicians on ICD-10 coding accuracy. The results were significant: Ambience’s AI demonstrated a 27% relative improvement in coding performance compared to the expert physician baseline, suggesting the model could help eliminate up to one quarter of the coding errors even the most seasoned clinicians make.

About Ambience Healthcare
Ambience Healthcare is the leading AI platform for clinical documentation, CDI, and coding-built to ensure compliance, eliminate administrative burden, and improve care delivery. Trusted by top health systems across North America, Ambience’s platform is live across outpatient, emergency, and inpatient settings, supporting more than 100 specialties with real-time, coding-aware documentation. The platform integrates directly with Epic, Oracle Cerner, athenahealth, and other major EHRs. Founded in 2020 by Mike Ng and Nikhil Buduma, Ambience is headquartered in San Francisco and backed by Andreessen Horowitz, OpenAI Startup Fund, Kleiner Perkins, and other leading investors.

Media Contact
Karina Stabile
Aria Marketing for Ambience Healthcare
kstabile@ariamarketing.com
516-317-5835

SOURCE: Ambience

View the original press release on ACCESS Newswire

AI-Native Analytics Platform That Understands Your Business – and Your Developers

SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2025 / GoodData today announced the general availability of GoodData AI, a next-generation analytics platform that places AI at every layer of the data stack – from raw-data ingestion to governed insight delivery – without compromising trust or compliance.

Why GoodData AI Stands Apart

GoodData AI is designed for enterprises that require trust, scalability, and extensibility. Its architecture is built around these foundational principles:

• Composable by design: Embedded, white-labeled, and API-first; built for developers to connect with any AI stack.

• Semantic layer and ontology: The only AI analytics engine that natively understands your business logic, ensuring every answer is both consistent and metric-perfect.

• Model Context Protocol (MCP) Support: Enables real-time, cross-system context that makes AI relevant. GoodData’s new MCP Server Beta program is now available!

• AI you can trust: No data ever leaves your environment; every insight is explainable, auditable, and private by default.

• Analytics as Code: Turns GenAI from an opaque magic box into a governed, testable, and repeatable artifact within the analytics release cycle.

Roman Stanek, Founder & CEO of GoodData, said:

“Most generative AI pilots stall because they rely on ungoverned data. GoodData AI combines an open Analytics Lake, an Intelligent Semantic Layer, and AI Anywhere into one unified product. Our customers receive reliable insights instantly – directly in their apps and workflows – without needing any re-architecture.”

Core GoodData AI Capabilities

• AI Anywhere: Supports natural language interactions across various interfaces – within GoodData UI or embedded in your applications, with full white-label options available.

• Intelligent Semantic Layer: Uses domain ontologies and semantic models to ensure AI understands and speaks the language of your business.

• Natural Language Insights: Offers conversational data interactions, generating accurate answers, visualizations, and actionable suggestions.

• AI-Ready Analytics Lake: Ensures high-quality, unified data, facilitating scalable AI operations.

• Developer Tools and APIs: Provides flexible, API-first architecture for integration and automation within enterprise apps.

What Customers & Partners Are Saying About GoodData AI

“The intelligent semantic layer in GoodData gives us confidence. We know the data behind every AI-generated insight is consistent, reliable, and ready for action.”

Wagner Nascimento Filho, Development Manager for Analytics & IAM at TOTVS

“We’re thrilled to partner with GoodData to bring the power of white-labeled AI-driven analytics directly to our customers. GoodData’s natural language capabilities will allow our customers to interact with their data conversationally, making it easier than ever for our customers to generate insights and visualize results rapidly.”

Manoj Kumar, CTO at Atheer

“GoodData AI makes complex data easy to understand without requiring deep technical knowledge, which aligns perfectly with our mission at Salted CX. With GoodData AI’s context-aware metadata and Salted CX’s content analysis, we’re able to provide our customers with deeper analytics and understanding of conversations with their agents and bots.”

Simon Vostry, Co-Founder & CEO at Salted CX

Availability & Pricing

GoodData AI is available today on AWS, Azure, GCP, and private-cloud Kubernetes. Pricing starts with a Community tier (three users, one model route), scaling to Enterprise and OEM plans that bundle lake-compute credits and LLM token packs.

Looking Ahead

GoodData AI marks the beginning of a new era of BI, where AI isn’t just a bolt-on assistant but a core, intelligent layer within the analytics stack. As the platform evolves, expect deeper orchestration and integration, and more intuitive user experiences, delivered at scale, securely, and in full alignment with enterprise needs.

AI will continue to expand across every layer of the GoodData platform, powering intelligence everywhere it’s needed.

About GoodData

GoodData is the AI-native analytics platform built for speed, scale, and trust, helping companies deliver real-time insights – embedded, branded, and everywhere your users need them.

Founded in 2007, and with offices in both the U.S. and Europe, GoodData serves over 140,000 of the world’s top companies and 3.2 million users, helping them drive meaningful change and maximize the value of their data.

For more information, visit GoodData’s website and follow GoodData on LinkedIn, YouTube, and Medium.

GoodData Contact

press@gooddata.com

©2025, GoodData Corporation. All rights reserved. GoodData and the GoodData logo are registered trademarks of GoodData Corporation in the United States and other jurisdictions. Other names used herein may be trademarks of their respective owners.

SOURCE: GoodData

View the original press release on ACCESS Newswire

AUSTIN, TX / ACCESS Newswire / May 27, 2025 / Volcon ePowersports (NASDAQ:VLCN) (“Volcon” or the “Company”)) the first all-electric, off-road powersports company, received its first purchase order from Advanced EV for 1,000 golf carts.

This initial order will be used by Volcon to conduct market testing of a new golf cart model developed in conjunction with Super Sonic under the distribution agreement with Volcon previously announced in February 2025. The order represents a first step in exploring a broader relationship between the two companies.

“We’re excited to supply Advanced EV with this test order and see it as a strong foundation for future collaboration,” said John Kim, CEO, Volcon. “As an OEM manufacturing partner, we look forward to the opportunity to help bring innovative and high-quality products to Advanced EV’s dealer network and customer base.”

Birju Patel, CEO of Advanced EV, added, “We’re pleased to be working with Volcon on this initial test order. Their distribution capabilities and ability to move quickly make them a valuable partner as we explore new product offerings to serve our growing customer base.”

“This is the second multi-million dollar deal in the last five weeks,” said Josh Rasmussen, CSO of Volcon. “We’re excited to see the growth trajectory for Volcon and believe this momentum signals a strong future ahead.”

The Company also adds that it has resumed its share repurchase program.

About Volcon
Based in the Austin, Texas area, Volcon was founded as the first all-electric power sports company producing high-quality and sustainable electric vehicles for the outdoor community. Volcon electric vehicles are the future of off-roading, not only because of their environmental benefits but also because of their near-silent operation, which allows for a more immersive outdoor experience.

Volcon’s vehicle roadmap includes both motorcycles and UTVs. Its first product, the innovative Grunt, began shipping to customers in late 2021 and combines a fat-tired physique with high-torque electric power and a near-silent drive train. The Volcon Grunt EVO, an evolution of the original Grunt with a belt drive, an improved suspension, and seat, began shipping to customers in October 2023. The Brat is Volcon’s first foray into the wildly popular eBike market for both on-road and off-road riding and is currently being delivered to dealers across North America. In 2024, Volcon entered the rapidly expanding LUV and UTV market and shipped its first production MN1 unit in October 2024. The new MN1 and HF1 products empower the driver to explore the outdoors in a new and unique way that gas-powered units cannot. They offer the same thrilling performance of a standard LUV / UTV without the noise (or pollution), allowing the driver to explore the outdoors with all their senses.

Volcon Contacts
For Media: media@volcon.com
For Dealers: dealers@volcon.com
For Investors: investors@volcon.com
For Marketing: marketing@volcon.com

For more information on Volcon or to learn more about its complete eBike, motorcycle and side-by-side line-up, visit: www.volcon.com

Forward-Looking Statements
Some of the statements in this release referenced in this release are forward-looking statements, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, whether the full purchase order will be fulfilled and when the units will be delivered and when share repurchases will be completed. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, which are available on the SEC’s website, www.sec.gov.

SOURCE: Volcon, Inc.

View the original press release on ACCESS Newswire

Support for Bitcoin and Stablecoins on Lightning Underscores ALT5’s Commitment to Scalable, Real-Time Settlement Infrastructure

LAS VEGAS, NEVADA / ACCESS Newswire / May 27, 2025 / ALT5 Sigma Corporation (the “Company” or “ALT5”) (NASDAQ:ALTS)(FRA:5AR1), a fintech company that delivers blockchain-powered payment and trading infrastructure for global merchants and financial institutions, today announced that Lightning Network capabilities are now live on its platform.

This upgrade enables instant, low-cost Bitcoin payments on ALT5 and lays the foundation for Tether (USDT) stablecoin support over Lightning, delivering a powerful combination of speed, stability, and cost-efficiency for enterprises that depend on high-frequency digital transactions.

ALT5’s Lightning integration is made possible through Voltage, a leading provider of enterprise-grade Lightning infrastructure. By embedding Lightning into its Crypto-as-a-Service ecosystem, ALT5 enables clients to benefit from real-time settlement, whether transacting in Bitcoin or increasingly in stablecoins such as USDT.

“Real-time payments are no longer optional-they’re becoming essential for modern finance,” said Peter Tassiopoulos, CEO of ALT5 Sigma. “With Lightning now available on our platform, we’re giving institutions a direct path to instant Bitcoin payments and preparing for the growing demand for stablecoin settlement over Lightning.”

The introduction of Lightning on ALT5 unlocks a new class of use cases for digital asset settlement, particularly in cross-border commerce, high-frequency trading, and global merchant payments. Clients can now dramatically reduce fees and confirmation times, while maintaining the robust compliance and operational controls built into ALT5’s infrastructure.

“The ability to move Tether over Lightning is an inflection point for the industry,” said Graham Krizek, CEO of Voltage. “It’s a stable, scalable payment method layered on top of Bitcoin’s security and ALT5 is making that future accessible to institutions today.”

The evolving potential for stablecoin settlement over Lightning presents new opportunities for financial platforms. ALT5 is closely monitoring this space as part of its ongoing commitment to delivering scalable, future-ready payment infrastructure for global enterprises.

With Lightning now integrated, ALT5’s platform supports a full range of crypto transaction protocols, enabling real-time settlement across Bitcoin, stablecoins, and multiple networks. Regardless of the asset or underlying technology, transactions can now be initiated, routed, and settled through ALT5’s unified infrastructure.

For more information on ALT5 Sigma’s payment solutions and its integration with Voltage, visit http://alt5sigma.com/.

About ALT5 Sigma

ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) is a fintech company, providing next generation blockchain-powered technologies for tokenization, trading, clearing settlement, payment and safe keeping of digital assets. The Company is one of the constituents of the Russell Microcap Index, as of June 28, 2024.

Founded in 2018, ALT5 Sigma, Inc. (a wholly owned subsidiary of ALT5 Sigma Corporation), provides next-generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Sigma, Inc., through its subsidiaries, offers two main platforms to its customers: “ALT5 Pay” and “ALT5 Prime.” ALT5 Sigma has processed over $5 billion USD in cryptocurrency transactions since inception.

ALT5 Pay is an award-winning cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets.

ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named “ALT5 Pro” that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime’s FIX API, as well as through Broadridge Financial Solutions’ NYFIX gateway for approved customers.

The Company is working on the separation of our biotech business that will move forward under “Alyea Therapeutics Corporation.” Through its biotech activities, the Company is focused on bringing to market drugs with non-addictive pain-relieving properties to treat conditions that cause chronic or severe pain. Our patented product, a novel formulation of low-dose naltrexone (JAN123), is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. The FDA has granted Jan123 Orphan Drug Designation for treatment of CRPS.

About Voltage

Voltage is a leading enterprise Lightning Network provider, offering scalable infrastructure for businesses looking to integrate instant, low-cost Bitcoin payments. With a mission to drive mainstream Lightning adoption, Voltage provides businesses with the tools they need to leverage Bitcoin’s fastest and most efficient payment layer.

Forward Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5’s platforms and business that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5’s services, and technology challenges for future growth or expansion. This press release also may contain statements or links relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as “continue”, “expect”, “intend”, “will”, “hope”, “should”, “would”, “may”, “potential”, and other similar expressions. Such statements reflect the Company’s current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies.

Many factors could cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in the Company’s filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Media Contact

Media/Investor Relations
ALT5 Sigma Corporation
ir@alt5sigma.com
1-800-400-2247

SOURCE: ALT5 Sigma Corp.

View the original press release on ACCESS Newswire

SYDNEY, AU / ACCESS Newswire / May 27, 2025 / Dateline Resources Limited (ASX:DTR)(OTC PINK:DTREF), a leading Australian exploration company advancing high-potential mineral projects in North America, is thrilled to announce promising exploration results from its 100%-owned Colosseum Rare Earth Element (REE) and Gold Project in California’s mineral-rich Walker Lane Trend, East San Bernardino County. As of May 21, 2025, recent field mapping and geochemical sampling have revealed a significantly expanded mineralized system, with the potential to unlock substantial REE opportunities and grow the project’s 1.1-million-ounce gold resource, positioning Colosseum as a cornerstone asset for Dateline.

Groundbreaking Exploration Discoveries

Recent exploration efforts have focused on felsite (rhyolite) outcrops located 200-900 meters west and southwest of the Colosseum open pits, mined in the late 1980s and early 1990s. These findings provide tangible evidence of a broader intrusion-related mineral system that could host significant REE deposits and additional gold zones beyond the historically worked areas.

Key Exploration Highlights:

• Strategic REE Potential: Located less than 10 km from the Mountain Pass Rare Earth mine, Colosseum’s mantle-derived rocks and carbonatite associations suggest a promising REE initiative. The presence of pathfinder elements and geological similarities to nearby REE deposits indicate potential for millions of tons of critical minerals like neodymium and dysprosium, essential for clean energy, electronics, and defense technologies.

• Expanded Mineralized Footprint: Geochemical anomalies in felsite samples, including elevated levels of antimony (Sb), bismuth (Bi), tellurium (Te), arsenic (As), and traces of silver (Ag), indicate a distal halo typical of intrusion-related gold systems (IRGS), where gold and potentially REEs are concentrated in central zones at depth or along strike.

• New Felsite Outcrops: Newly identified felsite dykes align with the structural trends of the known breccia pipes, following an orthogonal fracture system and ring-dyke pattern associated with an underlying intrusive body. These dykes, observed in a semi-circular pattern around the pits, are satellites to the main felsite intrusion, potentially feeding additional REE- and gold-bearing structures.

• Untapped Potential: Historical exploration was limited to 641 drill holes targeting two breccia pipes within or near the pits, leaving vast areas of the claims untested. No comprehensive property-wide geochemical survey was previously conducted, highlighting significant opportunities for new REE and gold discoveries.

• Exploration Targets: Priority zones include breccia pipe extensions and felsite-hosted mineralization along the established structural trends, with a maiden drill program planned to test for both REE and gold potential.

Current Resource and Geological Model

The Colosseum Project is strategically positioned to capitalize on its REE potential, complemented by a robust gold resource. The gold component hosts a JORC-2012 compliant Mineral Resource estimate, announced on June 6, 2024, totaling 27.1 million tonnes at 1.26 grams per tonne (g/t) gold, equating to 1.1 million ounces, categorized as:

• Measured: 455,000 ounces at 1.47 g/t (41%, highest confidence).

• Indicated: 281,000 ounces at 1.21 g/t (26%, moderate confidence).

• Inferred: 364,000 ounces at 1.10 g/t (33%, preliminary estimate).

Geological mapping confirms that the newly discovered felsite dykes align with the deposit’s structural framework, characterized by a pronounced orthogonal fracture system and a ring-dyke pattern tied to an underlying intrusive body. Surface mapping prior to open-pit mining illustrates a semi-circular pattern of felsite (rhyolite) breccia outcrops surrounding the Colosseum pits, consistent with the historic geological model (Source: Geology Notes, 1983). The felsite outcrops, located 200-900 meters west and southwest of the north and south pits, align with the modeled subsurface felsite body, indicating potential extensions of breccia pipes hosting both REEs and gold (see Figures 1-3 in the original exploration report).

Geochemical and Alteration Insights

Detailed geochemical analysis of the felsite samples provides critical insights into the mineralizing system, supporting both REE and gold potential:

• Magma Evolution: The felsite is indicative of a highly fractionated, moderately oxidized granitic melt. Abundant zircon (zirconium-rich minerals) and early magnetite crystallization suggest extensive fractional crystallization, concentrating incompatible elements like bismuth (Bi) and tellurium (Te), typical of IRGS deposits and often associated with REE-enriched systems.

• Alteration Patterns: Intense potassic alteration (secondary K-feldspar and biotite) and phyllic alteration (sericite-quartz-pyrite overprint) confirm significant hydrothermal fluid activity, a key driver of both REE and gold deposition. A ~2-meter-wide felsite dyke oriented southwest exhibits alteration patterns consistent with the mineralized breccia pipes (see Figure 4 in the original exploration report).

• Pathfinder Elements: Elevated levels of Bi, Te, Sb, As, and traces of Ag, often associated with bismuth-telluride minerals in gold deposits, also align with REE-bearing systems. These elements form a distal geochemical halo, suggesting that the surface exposures lie peripheral to a mineral-rich core potentially containing both REEs and gold.

The geochemical and alteration profile matches the outer zone of an intrusion-related mineral system, adding credence to the possibility of a large, zoned system at Colosseum with significant REE and gold potential.

Mineral Potential and Quantities

Confirmed Minerals (June 6, 2024 Resource Estimate):

• Gold (Au): 1.1 million ounces from 27.1 million tons at 1.26 g/t.

  • Measured: 455,000 oz at 1.47 g/t.

  • Indicated: 281,000 oz at 1.21 g/t.

  • Inferred: 364,000 oz at 1.10 g/t.

• Pathfinder Elements: Trace amounts of antimony (Sb), bismuth (Bi), tellurium (Te), arsenic (As), and silver (Ag) in felsite samples, indicating a fertile mineral system.

Additional Minerals:

• REEs: Proximity to the Mountain Pass mine and the presence of mantle-derived rocks and carbonatite associations suggest potential for millions of tons of REEs, such as neodymium or dysprosium, pending further exploration.

• Gold: Breccia pipe extensions or deeper felsite-hosted zones could add hundreds of thousands of ounces, pending drilling confirmation.

• Pathfinder Elements: Sb, Bi, Te, As, and Ag may be economically viable as byproducts in IRGS deposits if gold and REE grades are high.

Historical Context and Untapped Opportunities

Historical exploration at Colosseum was narrowly focused, with all 641 drill holes targeting the two main breccia pipes within or near the open pits for gold. No drilling or comprehensive geochemical surveys were conducted outside these areas, and REE potential was not systematically explored. The recent discovery of pathfinder anomalies in felsite outcrops, enriched in Bi, Te, Sb, and As, represents evidence of mineralization beyond the mined zones, highlighting the potential for significant new REE and gold discoveries.

Strategic Exploration Roadmap

Dateline is advancing a robust exploration program to capitalize on the REE and gold potential:

• REE Investigation: Quantifying REE potential in mantle-derived rocks and carbonatites, leveraging proximity to the Mountain Pass Rare Earth mine.

• Expanded Geochemical Sampling: Extending surface sampling along the projected trend of the felsite dykes to delineate the mineralized corridor for both REEs and gold.

• Maiden Drill Program: Targeting breccia pipe extensions at depth beneath the newly identified felsite outcrops and adjacent structural zones mirroring the ring-dyke pattern to test for REE and gold deposits.

• Geophysical Surveys: Evaluating geophysical technology to refine drill targets and further map subsurface extensions of the felsite intrusion for REE and gold potential.

Managing Director Stephen Baghdadi stated, “The Colosseum Project is poised for transformative growth. These findings confirm a larger mineral system, with the potential to significantly expand our 1.1-million-ounce gold resource and establish Colosseum as a key REE player. We are committed to aggressively moving the project forward and delivering exceptional value to our stakeholders.”

Economic Outlook

On May 23, 2025, Dateline announced updated economics for the Colosseum Gold Project, generating an NPV6.5 of US$550 million and an IRR of 61% using a gold price of US$2,900/oz. The emerging REE potential and expanded mineralized footprint further enhance the project’s economic viability, positioning it as a strategic asset for critical minerals and precious metals.

About Dateline Resources Limited

Dateline Resources Limited (ASX: DTR) is an Australian publicly listed company focused on high-value mining and exploration in North America. The Colosseum REE and Gold Project, located in California’s Walker Lane Trend, is a flagship asset with emerging REE potential and proven gold resources.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of applicable securities laws. These statements relate to future events or future performance and include, but are not limited to, statements regarding the potential of the Colosseum Project, the expected benefits of the OTCQB listing, the company’s plans for future development, and the strategic importance of the project for U.S. critical minerals supply. Forward-looking statements are based on the company’s current expectations, estimates, and projections, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to: fluctuations in the prices of gold and rare earth elements; changes in regulatory requirements or permitting processes; geological or technical challenges in exploration and development; market conditions affecting the company’s ability to raise capital; environmental or social factors impacting operations; risks associated with the OTCQB listing process or trading on a new market; environmental and permitting risks associated with operating in a national preserve; uncertainty regarding the delineation of a mineable rare earth elements resource; risks related to the company’s ability to secure necessary funding for project development; and potential changes in government policies or priorities affecting the critical minerals sector. The company cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company does not undertake any obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Competent Person Statement

The exploration data has been reviewed by Mr. Greg Hall, a Chartered Professional of the Australasian Institute of Mining and Metallurgy (CP-IMM) and Non-Executive Director of Dateline. Mr. Hall, with extensive experience in IRGS-style mineralization, qualifies as a Competent Person under the JORC Code and consents to the inclusion of this information.

Contact Information

For further details, please contact:

• Stephen Baghdadi, Managing Director, +61 2 9375 2353, www.datelineresources.com.au

• Andrew Rowell, White Noise Communications, +61 400 466 226, andrew@whitenoisecomms.com

Follow Dateline on X: @Dateline_DTR

This announcement is authorized for release by the Dateline Resources Limited Board of Directors.

SOURCE: Dateline Resources Limited

View the original press release on ACCESS Newswire

LAS VEGAS, NEVADA / ACCESS Newswire / May 27, 2025 / Avant Technologies Inc. (OTCQB:AVAI) (“Avant” or the “Company”), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies are exploring options to integrate the early detection of dementia into Ainnova’s proprietary, AI-powered platform technology, Vision AI. The addition would reinforce the Company’s mission of expanding AI-powered early detection and preventative health solutions across the globe.

Currently, the Company has identified a promising patented early disease detection technology specializing in the early detection of dementia and is exploring its options to either license the technology globally or potentially acquire the technology altogether. The patented technology combines AI algorithms and hardware based on a 5-minute blood test. Adding the early detection of dementia would expand the offerings in the Company’s technology portfolio and enhance the broader vision of the partnership between Avant and Ainnova.

The success of the Company’s preventative screening platform involves the deployment of an automated, low-cost retinal imaging device integrated with the Vision AI platform to deliver comprehensive preventive risk screening. Presently, from just two retinal images, blood pressure and some lab test information, the Company’s system uses 4 integrated algorithms to assess risks for: (i) cardiovascular disease (CVD), (ii) type 2 diabetes, (iii) liver fibrosis, and (iv) chronic kidney disease (CKD).

Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said of the potential expansion of its technology portfolio, “This accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years. Adding the early detection of dementia that this patented technology presents us, would go a long way to making us a leader in the industry of early disease detection.”

About Ainnova Tech, Inc.

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

About Avant Technologies Inc.

Avant Technologies Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

More information about Avant can be found at https://avanttechnologies.com

You can also follow us on social media at:

https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

Contact:

Avant Technologies Inc.
info@avanttechnologies.com

SOURCE: Avant Technologies Inc.

View the original press release on ACCESS Newswire

CAMBRIDGE, MA / ACCESS Newswire / May 27, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:

Jefferies Global Health Care Conference, on Thursday, June 5^th at 10:30am ET

Goldman Sachs 46^th Annual Global Healthcare Conference, on Wednesday, June 11^th at 8:40am ET

A live webcast of each of these presentations will be available under “Events and Presentations” in the Investors section of the Moderna website.

investors.modernatx.com.

A replay of each webcast will be archived on Moderna’s website for at least 30 days following the presentation.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire